Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAFE-PCI: Empagliflozin for Prevention of Post-procedural Complications in T2DM
NCT05037695Phase 4Unknown
- Sponsor
- Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
- Start
- Jul 2021
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of empagliflozin in type 2 diabetes mellitus (T2DM), sponsored by Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo. Status: unknown.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05037695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05037695.